What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Jason B. Fleming spends much of his time researching Pancreatic cancer, Internal medicine, Adenocarcinoma, Neoadjuvant therapy and Cancer research.
Cancer covers he research in Pancreatic cancer.
Jason B. Fleming combines subjects such as Gastroenterology and Oncology with his study of Internal medicine.
His Adenocarcinoma research focuses on Pathology and how it relates to Primary tumor, Pancreatic disease, Monoclonal antibody and In vivo.
The Neoadjuvant therapy study combines topics in areas such as Survival rate, Pancreatectomy, Pancreaticoduodenectomy, Combined Modality Therapy and Radiology.
His Cancer research research is multidisciplinary, incorporating elements of Cell growth, Cancer stem cell, Immunology, KRAS and Signal transduction.
His most cited work include:
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States (2896 citations)
- Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway (1019 citations)
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function (637 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Pancreatic cancer, Internal medicine, Cancer research, Cancer and Surgery.
His research in Pancreatic cancer intersects with topics in Gemcitabine, Chemotherapy, Pathology, Radiology and Metastasis.
His work in Pathology addresses issues such as Pancreas, which are connected to fields such as Neuroendocrine tumors.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Oncology.
His Cancer research course of study focuses on KRAS and Oncogene.
His Cancer study integrates concerns from other disciplines, such as Stage and Immunology, Lymph node.
He most often published in these fields:
- Pancreatic cancer (40.90%)
- Internal medicine (33.57%)
- Cancer research (24.59%)
What were the highlights of his more recent work (between 2016-2021)?
- Pancreatic cancer (40.90%)
- Cancer research (24.59%)
- Internal medicine (33.57%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Pancreatic cancer, Cancer research, Internal medicine, Cancer and Oncology.
His Pancreatic cancer study incorporates themes from Stage, Carcinoma, Mitochondrion and Cell growth.
Jason B. Fleming has researched Cancer research in several fields, including Cell, Cancer cell, Oncogene, KRAS and Tumor progression.
As part of the same scientific family, Jason B. Fleming usually focuses on Internal medicine, concentrating on Gastroenterology and intersecting with Chemoradiotherapy.
His work carried out in the field of Cancer brings together such families of science as Dysplasia, Disease and Pathology.
His biological study spans a wide range of topics, including Survival analysis and Chemotherapy.
Between 2016 and 2021, his most popular works were:
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. (364 citations)
- MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. (177 citations)
- Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer (125 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
The scientist’s investigation covers issues in Pancreatic cancer, Cancer research, Internal medicine, Cancer and Neoadjuvant therapy.
His Pancreatic cancer research integrates issues from Signal transduction and Mitochondrion.
His Cancer research research includes elements of Cancer cell, KRAS and Cell growth.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Oncology.
His Cancer study combines topics in areas such as Autophagy, Mitophagy and Immunology.
His Neoadjuvant therapy study which covers Survival rate that intersects with Pancreaticoduodenectomy, Adenocarcinoma, Ampulla of Vater, Stage and Metastasis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
